Helix BioPharma Corp. Closes Private Placement

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced it has closed a private placement financing for gross proceeds of $3,000,000.

20201230 – HBP Press Release – Closes Private Placement